

国内版国际版

Microsoft Bing

Effect of inflammatory bowel disease treatments on patients with d

ALLIMAGESVIDEOS

Add the Give

8,170,000 ResultsAny time

Diabetes Mellitus and Inflammatory Bowel Disease - Full ...

<https://clinicaltrials.gov/ct2/show/NCT04105348>

Sep 26, 2019 · Amino-salicylates and antibiotics are step I drugs act on the intestinal lining and on presented inflammatory masses. Corticosteroids are step II drugs on failure of step I drugs for adequate control of the Inflammatory bowel disease and rapid relief of symptoms and inflammation. The immune modifying agents as azathioprine and 6 mercaptopurine are step III drugs on failure of the steroids.

Diisease Characteristics and Severity in Patients With ...

<https://www.ncbi.nlm.nih.gov/pubmed/31944255>

Jan 16, 2020 · Among IBD DM patients, the use of immunomodulators and/or biologics was not associated with further complications as measured by antibiotic use or hospitalizations. CONCLUSIONS:

Inflammatory Bowel Disease

Medical Condition

A group of intestinal disorders that cause inflammation of the digestive tract.

Common (More than 200,000 cases year in US)

Often requires lab test or imaging

Treatments can help manage conditi

Microsoft Bing

国内版

国际版

Effect of inflammatory bowel disease treatments on patients with di

🖨

📌

🔍

Sign in

☰

ALL

IMAGES

VIDEOS

3,130,000 Results

Any time

Diabetes Mellitus and Inflammatory Bowel Disease - Full ...

https://clinicaltrials.gov/ct2/show/NCT04105348

Sep 26, 2019 - Amino-salicylates and antibiotics are step I drugs act on the intestinal lining and on presented inflammatory masses. Corticosteroids are step II drugs on failure of step I drugs for adequate control of the inflammatory bowel disease and rapid relief of symptoms and inflammation. The immune modifying agents as azathioprine and 6 mercaptopurine are step III drugs on failure of the steroids.

Diabetes Mellitus and the Colon

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6049816

Jan 12, 2017 - Results in reduction in colonic bile acid (bile acids known for intestinal secretion, increased mucosal permeability, and acceleration of colonic transit) Cholestyramine 4 g once to twice daily Colostipol 1 g once to twice daily Colessevelam 625 mg three times daily to a ...

Cited by: 21      Author: Marc S. Piper, Richard J. Saad

Publish Year: 2017

PEOPLE ALSO ASK

How does inflammatory bowel disease affect a diabetic?

▼

Are there any anti inflammatory agents for diabetes?

▼

Is there a cure for inflammatory bowel disease?

▼

Inflammatory Bowel Disease

Medical Condition

A group of intestinal disorders that cause inflammation of the digestive tract. This causes abdominal pain, cramping and unexplained weight loss.

📊 Common (More than 200,000 cases per year in US)

🏥 Often requires lab test or imaging

💊 Treatments can help manage condition, no known cure

🕒 Can be lifelong

IBD is said to be the result of autoimmune reactions. Inflammatory bowel disease (IBD) presents as crohn's disease or ulcerative colitis. It may be characterized by diarrhea, abdominal pain and cramping, tiredness, and weight loss. Treatment of inflammatory bowel disease focuses on reducing inflammation that causes the symptoms which can eventually lead to complications. The treatment involves administering medication or performing surgery.

Symptoms

Symptoms may vary from mild to severe and include:

• Diarrhea


• Fever

• Fatigue

05-Jul-2021 09:52PM

2447 words • 5 matches • 4 sources

FAQ

 iThenticate®

63170\_Auto\_Edited.docx

Quotes Excluded  
Bibliography Excluded

3%  
similarity

**Name of Journal:** *World Journal of Diabetes*

**Manuscript NO:** 63170

**Manuscript Type:** MINIREVIEWS

**Effect of inflammatory bowel disease treatments on patients with diabetes mellitus**

**Effect of IBD treatments on patients with DM**

Joshua Ashley Jack Bower, Lauren O'Flynn, Rakhi Kakad, David Aldulaimi

Match Overview

1

Internet 24 words  
crawled on 08-Jul-2020  
[gut.bmj.com](#)

1%

2

Crossref 16 words  
[S. Ardizzone, A. Casanotti, G. Bianchi Porro, "Conventional ...  
light: the unmet needs", Digestive and Liver Disease Supplem](#)

1%

3

Crossref 13 words  
[K. Timper, P. Hruz, C. Beglinger, M. Y. Donath, "Infliximab in I...  
e Treatment of Crohn Disease and Type 1 Diabetes", Diabete](#)

1%

4

Internet 13 words  
crawled on 10-Nov-2020  
[patentscope.wipo.int](#)

1%

Page: 1 of 12

Text-Only Report

国内版

国际版

g

Effect of inflammatory bowel disease treatments on patients with c



ALL

IMAGES

VIDEOS

2,000,000 Results

Any time ▾

## Diabetes Mellitus and Inflammatory Bowel Disease - Full ...

<https://clinicaltrials.gov/ct2/show/NCT04105348> ▾

Sep 26, 2019 · Amino-salicylates and antibiotics are step I drugs act on the intestinal lining and on presented inflammatory masses. Corticosteroids are step II drugs on failure of step I drugs for adequate control of the Inflammatory bowel disease and rapid relief of symptoms and inflammation. The immune modifying agents as azathioprine and 6 mercaptopurine are step III drugs on failure of the steroids.

## Risks of inflammatory bowel disease treatment with ...

<https://pubmed.ncbi.nlm.nih.gov/24246990>

Background: Glucocorticosteroids and aminosalicylates, mainly mesalazine (5-ASA), are both standard therapeutics in the **treatment of inflammatory bowel disease (IBD) patients**. The glucocorticosteroids are highly effective in inducing remission in both ulcerative colitis and Crohn's **disease**, but their use is limited by the high incidence and the potentially serious nature of adverse events.

Cited by: 65

Author: Ivanka Curkovic, Marco Egbring, Gerd A. ...

Publish Year: 2013

### PEOPLE ALSO ASK

Is there a link between diabetes and inflammatory bowel disease? ▾

Is there a cure for inflammatory bowel disease? ▾

What is the management of type 2 diabetes? ▾

Why is diabetes not traditionally associated with the GI tract? ▾

Feedback

## Disease Characteristics and Severity in Patients With ...

<https://pubmed.ncbi.nlm.nih.gov/31944255>

Among IBD DM patients, the use of immunomodulators and/or biologics was not associated with further complications as measured by antibiotic use or hospitalizations. Conclusions: This study of a large IBD cohort suggests that DM in IBD may be associated with **increased disease** severity and that there may be room for increasing use of highly effective immunomodulator and/or biologic agents in this group.